121 related articles for article (PubMed ID: 37897124)
1. Use of apixaban in children awaiting heart transplantation.
Benvenuto V; Hartje-Dunn C; Vo L; Hellinger A; Esteso P; Fynn-Thompson F; VanderPluym C
Pediatr Transplant; 2024 Feb; 28(1):e14632. PubMed ID: 37897124
[TBL] [Abstract][Full Text] [Related]
2. Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease.
VanderPluym C; Esteso P; Ankola A; Hellinger A; Ventresco C; Hawkins B; Kobayashi RL; Williams R; Cetatoiu MA; Gauvreau K; Esch JJ
J Thromb Haemost; 2023 Jun; 21(6):1601-1609. PubMed ID: 36921920
[TBL] [Abstract][Full Text] [Related]
3. Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients.
Salerno DM; Thornberg ME; Lange NW; Hedvat J; Robbins H; Brown RS; Jennings DL; Scheffert J
Clin Transplant; 2021 Dec; 35(12):e14396. PubMed ID: 34165845
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
5. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
Jawitz OK; Wang TY; Lopes RD; Chavez A; Boyer B; Kim H; Anstrom KJ; Becker RC; Blackstone E; Ruel M; Thourani VH; Puskas JD; Gerdisch MW; Johnston D; Capps S; Alexander JH; Svensson LG
Am Heart J; 2020 Sep; 227():91-99. PubMed ID: 32693197
[TBL] [Abstract][Full Text] [Related]
7. The utilization and safety of apixaban for therapeutic anticoagulation in heart transplant population requiring routine endomyocardial biopsies.
Lindauer KE; Ingemi AI; McMahon MR; Lichvar A; Baran DA; Cameron C; Badiye A; Sawey EJ; Old W; Yao A; Yehya A; Herre JM
Clin Transplant; 2022 Dec; 36(12):e14828. PubMed ID: 36194340
[TBL] [Abstract][Full Text] [Related]
8. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
Shin H; Cho MC; Kim RB; Kim CH; Choi NC; Kim SK; Koh EH
J Thromb Thrombolysis; 2018 Feb; 45(2):250-256. PubMed ID: 29198080
[TBL] [Abstract][Full Text] [Related]
9. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
[TBL] [Abstract][Full Text] [Related]
10. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
Zochert S; Oltman KM; Elgersma BM; Hellwig TR; Gulseth MP
Am J Health Syst Pharm; 2019 Apr; 76(8):505-511. PubMed ID: 31361865
[TBL] [Abstract][Full Text] [Related]
11. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
12. Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system.
Jakowenko N; Nguyen S; Ruegger M; Dinh A; Salazar E; Donahue KR
Thromb Res; 2020 Dec; 196():276-282. PubMed ID: 32947066
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists.
Touma L; Filion KB; Atallah R; Eberg M; Eisenberg MJ
Am J Cardiol; 2015 Feb; 115(4):533-41. PubMed ID: 25547937
[TBL] [Abstract][Full Text] [Related]
14. Influence of age on the relationship between apixaban concentration and anti-factor Xa activity in older patients with non-valvular atrial fibrillation.
Kalaria SN; Zhu H; Liu Q; Florian J; Wang Y; Schwartz J
Int J Cardiol; 2021 May; 331():109-113. PubMed ID: 33529664
[TBL] [Abstract][Full Text] [Related]
15. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
16. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
[TBL] [Abstract][Full Text] [Related]
17. Apixaban Anticoagulation in Children and Young Adults Supported With the HeartMate 3 Ventricular Assist Device.
Kobayashi RL; Cetatoiu MA; Esteso P; Ventresco C; Hawkins B; Daly KP; Blume ED; Fynn-Thompson F; VanderPluym C
ASAIO J; 2023 Jun; 69(6):e267-e269. PubMed ID: 36763905
[TBL] [Abstract][Full Text] [Related]
18. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model.
Lester PA; Coleman DM; Diaz JA; Jackson TO; Hawley AE; Mathues AR; Grant BT; Knabb RM; Ramacciotti E; Frost CE; Song Y; Wakefield TW; Myers DD
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):942-948. PubMed ID: 28232327
[TBL] [Abstract][Full Text] [Related]
19. Major bleeding with apixaban in atrial fibrillation: patient characteristics, management, and outcomes.
Eisho S; Salem NM; Hoffman JL; Koerber JM; Smythe MA
Hosp Pract (1995); 2018 Oct; 46(4):165-169. PubMed ID: 30058431
[TBL] [Abstract][Full Text] [Related]
20. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
